每經AI快訊，有投(tou)資(zi)者在投(tou)資(zi)者互動平臺提(ti)問(wen)：如(ru)果FDA審批通過貴公(gong)司的注射用(yong)紫杉(shan)(shan)醇(chun)（白(bai)蛋(dan)白(bai)結合(he)型(xing)），貴公(gong)司能否第(di)一時間組(zu)織生(sheng)產？預(yu)計產能多少？近期，貴公(gong)司受委托(tuo)生(sheng)產著(zhu)名抗(kang)艾滋病藥物，如(ru)果注射用(yong)紫杉(shan)(shan)醇(chun)（白(bai)蛋(dan)白(bai)結合(he)型(xing)）銷量急(ji)速(su)擴(kuo)大，貴公(gong)司準(zhun)備如(ru)何應對生(sheng)產能力不足的問(wen)題(ti)？

雙(shuang)成(cheng)藥(yao)業（002693.SZ）11月(yue)4日在投資者互動平臺表示，公(gong)(gong)司(si)的注射用(yong)紫杉(shan)醇（白蛋(dan)白結合型）生(sheng)(sheng)產廠(chang)地在公(gong)(gong)司(si)的控股(gu)子公(gong)(gong)司(si)寧波雙(shuang)成(cheng)生(sheng)(sheng)產，公(gong)(gong)司(si)受(shou)托品種注射用(yong)艾博韋泰(tai)在雙(shuang)成(cheng)藥(yao)業海口廠(chang)地生(sheng)(sheng)產。

(記者 畢陸名)

免責聲明(ming)：本文內容與數據(ju)僅供(gong)參考，不構成投資建議，使用前(qian)核實。據(ju)此(ci)操(cao)作(zuo)，風險自擔。